Annual report pursuant to Section 13 and 15(d)

Description of Business and Summary of Significant Accounting Policies - Additional Information (Detail)

v3.24.0.1
Description of Business and Summary of Significant Accounting Policies - Additional Information (Detail)
1 Months Ended 3 Months Ended 12 Months Ended
Jun. 01, 2017
USD ($)
Feb. 01, 2012
USD ($)
Dec. 31, 2005
USD ($)
Nov. 30, 2023
USD ($)
Nov. 30, 2022
USD ($)
Nov. 30, 2023
USD ($)
Unit
Segment
Nov. 30, 2022
USD ($)
shares
Business, Basis of Presentation and Significant Accounting Policies [Line Items]              
Number of reportable segments | Segment           3  
Concentration risk related to supplier           The Company depends on one supplier for the source of its collection kits  
Deferred revenue       $ 50,891,353   $ 50,891,353  
Warranty payment $ 100,000 $ 75,000 $ 50,000        
Commission paid           41,056 $ 50,977
Additional capitalized contract acquisition costs, net of amortization expense           114,139 109,673
Impairment of contract assets           0 0
Impairment of public inventory       3,737,133 $ 0 3,737,133 0
Impairment on long lived assets           0 0
Uncertain tax provisions       $ 0 $ 0 0 0
Provisions for interest or penalties related to uncertain tax positions           0 0
Advertising cost included in selling, general and administrative expenses           952,586 755,921
Losses on marketable securities           51,000 (39,000)
Gain on interest rate swap           122,113 446,200
Payment warranty     $ 50,000        
Increased payment warranty $ 100,000 $ 75,000          
Stock-based option compensation expense           $ 817,000 $ 461,000
Employee Stock Incentive Plan [Member]              
Business, Basis of Presentation and Significant Accounting Policies [Line Items]              
Number of outstanding options excluded from computation of diluted earnings per share | shares             635,301
Duke University [Member]              
Business, Basis of Presentation and Significant Accounting Policies [Line Items]              
Contracted storage amortization period       16 years   16 years  
Umbilical Cord Blood and Cord Tissue Stem Cell Service and PrepaCyte-CB [Member] | Duke University [Member]              
Business, Basis of Presentation and Significant Accounting Policies [Line Items]              
Agreement expiration date           Jan. 31, 2025  
Inventory, in units | Unit           6,000  
Number of units, per month | Unit           36  
Maximum [Member] | Umbilical Cord Blood and Cord Tissue Stem Cell Service and PrepaCyte-CB [Member] | Duke University [Member]              
Business, Basis of Presentation and Significant Accounting Policies [Line Items]              
Inventory, in units | Unit           36  
Accounts Receivables [Member]              
Business, Basis of Presentation and Significant Accounting Policies [Line Items]              
Period of doubtful for accounts receivable due from client           30 days  
Option One [Member]              
Business, Basis of Presentation and Significant Accounting Policies [Line Items]              
Contracted storage amortization period       1 year   1 year  
Option Two [Member]              
Business, Basis of Presentation and Significant Accounting Policies [Line Items]              
Contracted storage amortization period       18 years   18 years  
Option Three [Member]              
Business, Basis of Presentation and Significant Accounting Policies [Line Items]              
Contracted storage amortization period       21 years   21 years  
Option Four [Member]              
Business, Basis of Presentation and Significant Accounting Policies [Line Items]              
Contracted storage amortization period           lifetime  
Contracted storage amortization description           The life-time storage plan is based on a life expectancy of 81 years, which is the current estimate by the Center for Disease Control for United States women’s life expectancy and concluded that additional data analysis would result in an immaterial difference in revenue.